{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:50:30Z","timestamp":1762876230548,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barr\u00e9 syndrome, immune thrombocytopenia, and immune-mediated thrombotic thrombocytopenic purpura, have been described. We present a case of a patient with hemophagocytic lymphohistiocytosis secondary to COVID-19 treated with tocilizumab with a marked biochemical improvement.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>In this case report\u00a0we present a Caucasian patient with COVID-19 who developed a marked elevation of inflammatory parameters with ferritin 36,023\u2009\u03bcg\/L, but also elevated C-reactive protein 334\u2009mg\/L and lactate dehydrogenase 1074\u2009U\/L, 1 week after admission to the intensive care unit. He met five of eight criteria for hemophagocytic lymphohistiocytosis, but he lacked the high fever and cytopenia seen in the majority of cases. He was treated with tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor, and over the next days, a rapid decrease in ferritin and C-reactive protein levels was observed. However, his respiratory failure only improved gradually, and he was weaned off\u00a0the respirator 11\u2009days later.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>COVID-19 may induce a hyperinflammatory clinical picture and in some cases develop into hemophagocytic lymphohistiocytosis. In our patient\u2019s case, therapeutic interleukin-6 blockade abrogated signs of hyperinflammation but did not seem to improve pulmonary function. Measurement of ferritin and C-reactive protein, as well as quantification of interleukin-6 on indication, should be performed in patients with severe COVID-19. Specific treatment in such patients must also be contemplated, preferably in randomized controlled trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02503-9","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:09:54Z","timestamp":1602716994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6768-541X","authenticated-orcid":false,"given":"Birgitte","family":"Tholin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit Teigen","family":"Hauge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Fehrle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor Henrik","family":"Tvedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2503_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet"},{"issue":"5","key":"2503_CR2","first-page":"1027","volume":"30","author":"O Lambotte","year":"2003","unstructured":"Lambotte O, Cacoub P, Costedoat N, Le Moel G, Amoura Z, Piette JC. High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol. 2003;30(5):1027\u20138.","journal-title":"J Rheumatol"},{"issue":"15","key":"2503_CR3","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041\u201352.","journal-title":"Blood"},{"issue":"6","key":"2503_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/ajcp\/aqw076","volume":"145","author":"F Debaugnies","year":"2016","unstructured":"Debaugnies F, Mahadeb B, Ferster A, et al. Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients. Am J Clin Pathol. 2016;145(6):862\u201370.","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2503_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10067-012-1998-0","volume":"31","author":"CI Lin","year":"2012","unstructured":"Lin CI, Yu HH, Lee JH, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol. 2012;31(8):1223\u201330.","journal-title":"Clin Rheumatol"},{"issue":"1 Suppl","key":"2503_CR6","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.bbmt.2009.11.014","volume":"16","author":"A Filipovich","year":"2010","unstructured":"Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2503_CR7","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954.","journal-title":"Int J Antimicrob Agents"},{"key":"2503_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fimmu.2020.00211","volume":"11","author":"C Zhao","year":"2020","unstructured":"Zhao C, Zhao W. NLRP3 inflammasome\u2014a key player in antiviral responses. Front Immunol. 2020;11:211.","journal-title":"Front Immunol"},{"issue":"6","key":"2503_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/jmv.25736","volume":"92","author":"M Bhattacharya","year":"2020","unstructured":"Bhattacharya M, Sharma AR, Patra P, et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach. J Med Virol. 2020;92(6):618\u201331.","journal-title":"J Med Virol"},{"issue":"5","key":"2503_CR10","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S2213-2600(20)30153-3","volume":"8","author":"CJ Tignanelli","year":"2020","unstructured":"Tignanelli CJ, Ingraham NE, Sparks MA, et al. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020;8(5):e30\u20131.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2503_CR11","first-page":"145","volume":"41","author":"Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention","year":"2020","unstructured":"Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145\u201351.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"issue":"5","key":"2503_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","volume":"17","author":"HY Zheng","year":"2020","unstructured":"Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541\u20133. https:\/\/doi.org\/10.1038\/s41423-020-0401-3.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"2503_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","volume":"126","author":"P Strati","year":"2015","unstructured":"Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126(4):454\u201362.","journal-title":"Blood"},{"issue":"1\u20133","key":"2503_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12026-010-8188-4","volume":"49","author":"MC Lanasa","year":"2011","unstructured":"Lanasa MC, Weinberg JB. Immunologic aspects of monoclonal B-cell lymphocytosis. Immunol Res. 2011;49(1\u20133):269\u201380.","journal-title":"Immunol Res"},{"key":"2503_CR15","doi-asserted-by":"publisher","first-page":"bcr2016219057","DOI":"10.1136\/bcr-2016-219057","volume":"2017","author":"C Bailey","year":"2017","unstructured":"Bailey C, Dearden C, Ardeshna K. Haemophagocytic lymphohistiocytosis as a consequence of untreated B-cell chronic lymphocytic leukaemia. BMJ Case Rep. 2017;2017:bcr2016219057.","journal-title":"BMJ Case Rep"},{"key":"2503_CR16","doi-asserted-by":"publisher","unstructured":"Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab.\u00a0Proc Natl Acad Sci U S A. 2020;117(20):10970-10975. https:\/\/doi.org\/10.1073\/pnas.2005615117.","DOI":"10.1073\/pnas.2005615117"},{"key":"2503_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","volume":"70","author":"M Del Giudice","year":"2018","unstructured":"Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61\u201375.","journal-title":"Brain Behav Immun"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-020-02503-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T23:22:48Z","timestamp":1634253768000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02503-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2503"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02503-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval from an ethics committee was not required according to national policy. Patient consent has been obtained and can be displayed upon request.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}